ALSA

Alight Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Wednesday, February 21, 2024
Professional Services, Technology, Data Analytics, Human Resources, Finance, Software, Cloud, Acquisition, Interest, Growth, Business process, Disclosure, As a service, Hosting, GAAP, TCV, Central Time, EPS, Opel, Professional services, ALSA

Alight, Inc. (NYSE: ALIT), a leading cloud-based provider of integrated digital human capital and business solutions, today reported results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Alight, Inc. (NYSE: ALIT), a leading cloud-based provider of integrated digital human capital and business solutions, today reported results for the fourth quarter and full year ended December 31, 2023.
  • “Our three-year transformation has generated significant momentum and enabled Alight to deliver strong 2023 results,” said Chief Executive Officer Stephan Scholl.
  • For the same reasons, we are unable to address the probable significance of the unavailable information, which could be material to future results.
  • A conference call to discuss the Company’s fourth quarter and full year 2023 financial results is scheduled for today, February 21, 2024 at 7:30 a.m. Central Time (8:30 a.m. Eastern Time).

ALSA Ventures launches novel Gene Therapy portfolio company Axovia Therapeutics to treat Ciliopathies

Retrieved on: 
Tuesday, September 19, 2023
Tissue, University College London, UCL, PRV, BBS1, Research, Paratriathlon, Disease, AAV, BBS, Acquisition, ALSA, Patient, Syndrome, Vazgen Safarian, Ciliopathy, FDA, Therapy, Health, Pharmaceutical industry, Vaccine, Nursing, Child, Voretigene neparvovec

LONDON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- ALSA Ventures , a UK-based, therapeutics-focused venture capital fund, announces the acquisition of Axovia Therapeutics Inc and the launch of a new portfolio company Axovia Therapeutics Ltd .

Key Points: 
  • LONDON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- ALSA Ventures , a UK-based, therapeutics-focused venture capital fund, announces the acquisition of Axovia Therapeutics Inc and the launch of a new portfolio company Axovia Therapeutics Ltd .
  • Axovia is developing the first gene therapies for ciliopathies and has a pipeline of products for these devastating diseases, including Bardet-Biedl Syndrome (BBS).
  • AXV101 is an AAV9-based gene therapy targeting retinal dystrophy associated with BBS in patients carrying biallelic mutations in the BBS1 gene.
  • Axovia Acting CEO Professor Phil Beales said the Axovia gene therapy platform gives hope to BBS patients worldwide.

Magewell Adds Duo of 4K Models to Eco Capture Family of M.2 Cards

Retrieved on: 
Wednesday, August 16, 2023
IBC, Eco, Exhibition, SDI, M.2, PCI Express, HDMI, DMA, ALSA, Sibling, CPU, DirectShow, 3G, Linux, V4L2, API, OEM, SDK, Telescopic sight

NANJING, China, Aug. 16, 2023 /PRNewswire/ -- Magewell today announced two new models in the company's Eco Capture family of ultra-compact, power-efficient M.2 video capture cards. Hot on the heels of the recently introduced Eco Capture AIO M.2 -- which features selectable HDMI and SDI 1080p60 inputs -- the Eco Capture HDMI 4K Plus M.2 and Eco Capture 12G SDI 4K Plus M.2 capture 4K video at 60 frames per second over HDMI or SDI interfaces, respectively.

Key Points: 
  • Hot on the heels of the recently introduced Eco Capture AIO M.2 -- which features selectable HDMI and SDI 1080p60 inputs -- the Eco Capture HDMI 4K Plus M.2 and Eco Capture 12G SDI 4K Plus M.2 capture 4K video at 60 frames per second over HDMI or SDI interfaces, respectively.
  • The Eco Capture HDMI 4K Plus M.2 features an HDMI 2.0 interface, while the Eco Capture 12G SDI 4K Plus M.2 flexibly supports single-link 12G-SDI or quad-link 3G-SDI connectivity.
  • "The Eco Capture HDMI 4K Plus M.2 doubles the capture frame rate over our previous 4K HDMI model, while the Eco Capture 12G SDI 4K Plus M.2 adds input flexibility for multiple 4K SDI connectivity standards."
  • The Eco Capture HDMI 4K Plus M.2 is now shipping, with the Eco Capture 12G SDI 4K Plus M.2 expected to ship within the next 60 days.

ALSA Ventures launches Vantage Biosciences to treat Diabetic Eye Disease

Retrieved on: 
Wednesday, July 26, 2023
Therapy, Diabetes, Eye, Intravitreal injection, Paratriathlon, Inflammation, Acquisition, ALSA, Patient, Pharmaceutical industry

Diabetic eye disease is the leading cause of blindness in working age people and affects 1 in 3 people with diabetes – more than 382 million people worldwide.

Key Points: 
  • Diabetic eye disease is the leading cause of blindness in working age people and affects 1 in 3 people with diabetes – more than 382 million people worldwide.
  • The current standard of care for diabetic eye disease is an array of anti-VEGF drugs which target the microvascular sequalae that emerge in later stage disease and require regular invasive intravitreal injections.
  • Vantage Biosciences aims to provide an innovative oral treatment that is anticipated to interrupt chronic, low-grade inflammation of the neurovascular unit of the eye induced by diabetes, thereby abrogating the resulting microvascular angiopathy.
  • “We are excited to launch Vantage Biosciences and progress VX-01 into Phase 2 trials with the promise to provide a significant advance in an area of unmet need for the treatment of diabetic eye diseases,” stated Alek Safarian, ALSA Ventures’ Managing Partner.

Global Algaecides Market 2023 to 2028: Rising Incidences of Harmful Algal Blooms Drives Growth

Retrieved on: 
Monday, May 29, 2023
United States Environmental Protection Agency, Food, United States Department of Agriculture, Department of Science and Technology (Philippines), Research, Tilapia, Private, Statistics, Agriculture, Aquaculture, Lonza, Yearbook, Nutrient, Australian government debt, Temperature, Carbon, Salinity, Food and Agriculture Organization, Algal bloom, Climate change, ALSA, Investment, USDA, Pond, Male, Growth, Climate, Intensive word form, Geography, Nitrogen, Phosphorus, Fishery, Population growth, Lake, Fertilizer, Fine chemical

Thus, the expansion of the agricultural sector is expected to drive the demand for agricultural algaecides, thus augmenting market growth.

Key Points: 
  • Thus, the expansion of the agricultural sector is expected to drive the demand for agricultural algaecides, thus augmenting market growth.
  • The rise in the incidences of harmful algal blooms around the world, caused by various factors like the rise in climate change and industrial pollution is contributing towards the algaecides market growth.
  • With the rise in occurrences of algal blooms with, the growth of the algaecides market is likely to surge during the forecast period.
  • A well-established aquaculture market in the North American region is expected to drive the market of algaecides in this region.

Magewell Expands Eco Capture Family of Ultra-Compact, Power-Efficient M.2 Capture Cards

Retrieved on: 
Monday, February 27, 2023
BNC, V4L2, M.2, DirectShow, PCI Express, Linux, SDI, Engineering, HD, Microsoft Windows, CPU, HDMI, ALSA, OEM, NAB, SDK, API, 3G, NAB Show, Telescopic sight, Mobile phone

NANJING, China, Feb. 27, 2023 /PRNewswire/ -- Magewell has unveiled a new model in its Eco Capture family of ultra-compact, power-efficient, M.2 video capture cards. The new single-channel Eco Capture AIO M.2 provides both HDMI and SDI interfaces with embedded audio support for flexible input connectivity.

Key Points: 
  • Featuring both HDMI and SDI interfaces, Eco Capture AIO M.2 combines a space-efficient form factor with flexible input connectivity
    NANJING, China, Feb. 27, 2023 /PRNewswire/ -- Magewell has unveiled a new model in its Eco Capture family of ultra-compact, power-efficient, M.2 video capture cards.
  • Magewell will highlight the Eco Capture AIO M.2 and other new innovations in booth C5031 at the 2023 NAB Show in Las Vegas from April 16 to 19.
  • Magewell's Eco Capture cards offer systems integrators and OEM developers a high-performance video capture solution with low power consumption in a space-efficient form factor.
  • "Our Eco Capture family continues to be extremely popular for enabling robust, reliable video capture in space-constrained applications," said James Liu, VP of Engineering at Magewell.

Epsilogen Announces Completion of Oversubscribed £30.75 Million ($41.20 Million) Series B Financing

Retrieved on: 
Wednesday, March 2, 2022
Research, Finance, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Oncology, Therapy, Concept, Research, Parasitism, Immunoglobulin E, Immunoglobulin G, USD, Business, Growth, Series, Fund, Consultant, Cancer, Patient capital, Disease, ALSA, Public sector banks in India, UNPRI, Half-life, FR, Vaccine, Financial services, Management, Pharmaceutical industry, Epsilogen Ltd, Novartis Venture Fund, 3B FUTURE Health Fund II, British Patient Capital, Schroders Capital, Epidarex Capital, ALSA Ventures, EPSILOGEN LTD, NOVARTIS VENTURE FUND, 3B FUTURE HEALTH FUND II, BRITISH PATIENT CAPITAL, SCHRODERS CAPITAL, EPIDAREX CAPITAL, ALSA VENTURES

Epsilogen Ltd, a global leader in the development of novel immunoglobulin E (IgE) antibodies to treat cancer, announced it has secured 30.75 million ($41.20 million) in an oversubscribed Series B financing round.

Key Points: 
  • Epsilogen Ltd, a global leader in the development of novel immunoglobulin E (IgE) antibodies to treat cancer, announced it has secured 30.75 million ($41.20 million) in an oversubscribed Series B financing round.
  • The new syndicate joins founding Series A investor Epidarex Capital and Series A investor ALSA Ventures both of whom also committed further capital in this Series B fundraising round.
  • MOv18 IgE targets the folate receptor alpha (FR alpha) antigen and is the worlds first IgE antibody to enter the clinic.
  • Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer.

Automated Business Designs Releases the Candidate Compliance Portal to Help Staffing Companies Track Vaccination Statuses

Retrieved on: 
Thursday, January 13, 2022
ABD, Vaccination, National Association, Technology, Imagination, OSHA, CEO, Ultra, Customer success, Indian Railway Personnel Service, American, ALSA, Michigan Occupational Safety and Health Administration, ISSA, ASA, NAPS, Candidate, Occupational safety and health, American Staffing Association, Vaccine, Tunnel, Retail

CHICAGO, Jan. 13, 2022 /PRNewswire-PRWeb/ --Automated Business Designs, developers of Ultra-Staff EDGE staffing and recruiting software, released a breakthrough technology that will allow staffing companies to track candidate vaccination statuses within the Ultra-Staff EDGE applicant tracking system.

Key Points: 
  • CHICAGO, Jan. 13, 2022 /PRNewswire-PRWeb/ --Automated Business Designs, developers of Ultra-Staff EDGE staffing and recruiting software, released a breakthrough technology that will allow staffing companies to track candidate vaccination statuses within the Ultra-Staff EDGE applicant tracking system.
  • The Ultra-Staff EDGE Candidate Compliance Portal is available for free to all Ultra-Staff EDGE staffing software users.
  • "Staffing companies are faced with many challenges in today's employment industry," said Terri Roeslmeier, President and CEO at Automated Business Designs.
  • In addition to the portal being used for vaccination tracking, there are many other use cases where staffing companies can take advantage of the portal.

Automated Business Designs Partners with Brink's Money Paycard to Improve Payroll Processes for the Staffing Industry

Retrieved on: 
Wednesday, August 4, 2021
Business software, Brink's, Human resource management, Staffing software, Payroll, Staffing, Economy, Business, Articles

CHICAGO, August 4, 2021 /PRNewswire-PRWeb/ --Automated Business Designs, developers of Ultra-Staff EDGE staffing and recruiting software, have partnered with Brink's Money Paycard to bring a fully integrated

Key Points: 
  • CHICAGO, August 4, 2021 /PRNewswire-PRWeb/ --Automated Business Designs, developers of Ultra-Staff EDGE staffing and recruiting software, have partnered with Brink's Money Paycard to bring a fully integrated
    paycard staffing software solution to the industry.
  • The paycard integration in Ultra-Staff EDGE helps staffing companies simplify the payroll process and manage direct deposits onto an employee's paycard.
  • "We are eager to introduce our partnership with Brink's Money Paycard to the staffing industry," said Terri Roeslmeier, President and CEO of Automated Business Designs.
  • Brink's Money brings you the Brink's Money Paycard, a flexible solution for a paperless payroll.